Elevated platelet count is a strong predictor of poor prognosis in stage I non-small cell lung cancer patients. (11th March 2014)

• Record Type: Journal Article
• Authors: Ji, Yongling; Sheng, Liming; Du, Xianghui; Qiu, Guoqin; Su, Dan
• Is Part Of: Platelets. Volume 26:Number 2(2015:Mar.)
• Page Start: 138
• Page End: 142
• Publication Date: 2014-03-11
• Subjects: Lung cancer -- platelet, prognosis -- stage I disease; Blood platelets -- Periodicals; Blood Platelets -- Periodicals; 615.39
• DOI: 10.3109/09537104.2014.888547
• Languages: English
• ISSNs: 0953-7104

Abstract

Abstract: Stage I non-small cell lung cancer (NSCLC) show a highly variable biological behavior which cannot be accurately predicted by the current available prognostic markers. Platelet plays a significant role in cancer cell growth, progression and metastasis. This study aimed to investigate whether preoperative platelet count correlate with clinical prognosis in localized NSCLC. A retrospective clinical analysis was designed for a total of 234 stage I NSCLC patients in our hospital between October 2006 and December 2009. Pre-operative platelet count was measured. The association of platelet count with clinical pathological factors and patient outcome was evaluated. A significant correlation was detected between platelet count and tumor cell differentiation and T stage. Patients with elevated platelet count had an elevated risk of disease progression and death compared to patients with normal platelet count. The hazard ratio was 5.314 (95% confidence interval [CI] 2.750–10.269) for disease progression and 3.139 (95% CI 1.227–8.034) for death. The trend linking increasing platelet count with risk was also statistically significant for both the outcomes ( p < 0.05). These finding demonstrate that preoperative platelet count is a useful predictor of high risk progression and poor prognosis in stage I NSCLC patients.